肝细胞癌中巨组蛋白H2A1缺失诱导癌细胞干性
该研究探讨组蛋白变体巨组蛋白H2A1在肝细胞癌(HCC)癌症干细胞(CSC)分化中的作用。人HCC切片中巨组蛋白H2A1染色低频率与低分化、侵袭性HCC亚型显著相关;短发夹RNA介导巨组蛋白H2A1敲低使HCC细胞获得CSC样特征,并依赖核因子κB p65 Ser536磷酸化。
要点
- 人HCC切片中巨组蛋白H2A1染色低频率与低分化、侵袭性HCC亚型显著相关。
- 巨组蛋白H2A1敲低使HCC细胞获得CSC样特征、增殖减少、化疗耐药及干性代谢改变。
- 阻断核因子κB p65 Ser536磷酸化可抑制巨组蛋白H2A1敲低HCC细胞的CSC样特征。
核心结论
- 组蛋白变体巨组蛋白H2A1缺失在体外和体内赋予HCC细胞CSC样表型,该表型依赖核因子κB p65 Ser536磷酸化。
- 该通路可能为开发针对HCC的CSC-focused治疗提供有价值靶点。
研究设计与样本
- 研究使用人HCC组织切片及HCC细胞系,通过短发夹RNA敲低巨组蛋白H2A1,并在裸鼠体内注射细胞观察肿瘤生长。
主要发现
- 人HCC切片中巨组蛋白H2A1染色低频率与低分化、侵袭性HCC亚型显著相关。
- 短发夹RNA介导巨组蛋白H2A1敲低使HCC细胞获得CSC样特征,注射裸鼠后生长出显著更大且分化更差的肿瘤。
- 巨组蛋白H2A1缺失的HCC细胞增殖减少、对化疗药物耐药,并出现与缺氧反应增强和糖酵解增加一致的干性代谢改变。
- 巨组蛋白H2A1缺失增加一组干性相关基因表达,并驱动核因子κB p65通路过度激活。
- 阻断核因子κB p65 Ser536磷酸化可抑制巨组蛋白H2A1敲低HCC细胞中CSC样特征的出现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinomas (HCC) contain a subpopulation of cancer stem cells (CSCs), which exhibit stem cell-like features and are responsible for tumor relapse, metastasis, and chemoresistance. The development of effective treatments for HCC will depend on a molecular-level understanding of the specific pathways driving CSC emergence and stemness. MacroH2A1 is a variant of the histone H2A and an epigenetic regulator of stem-cell function, where it promotes differentiation and, conversely, acts as a barrier to somatic-cell reprogramming. Here, we focused on the role played by the histone variant macroH2A1 as a potential epigenetic factor promoting CSC differentiation. In human HCC sections we uncovered a significant correlation between low frequencies of macroH2A1 staining and advanced, aggressive HCC subtypes with poorly differentiated tumor phenotypes. Using HCC cell lines, we found that short hairpin RNA-mediated macroH2A1 knockdown induces acquisition of CSC-like features, including the growth of significantly larger and less differentiated tumors when injected into nude mice. MacroH2A1-depleted HCC cells also exhibited reduced proliferation, resistance to chemotherapeutic agents, and stem-like metabolic changes consistent with enhanced hypoxic responses and increased glycolysis. The loss of macroH2A1 increased expression of a panel of stemness-associated genes and drove hyperactivation of the nuclear factor kappa B p65 pathway. Blocking phosphorylation of nuclear factor kappa B p65 on Ser536 inhibited the emergence of CSC-like features in HCC cells knocked down for macroH2A1. Conclusion: The absence of histone variant macroH2A1 confers a CSC-like phenotype to HCC cells in vitro and in vivo that depends on Ser536 phosphorylation of nuclear factor kappa B p65; this pathway may hold valuable targets for the development of CSC-focused treatments for HCC. (Hepatology 2018;67:636-650).
引用
- Lo Re O, Fusilli C, Rappa F, et al. Induction of cancer cell stemness by depletion of macrohistone H2A1 in hepatocellular carcinoma. Hepatology. 2018. PMID: 28913935. doi:10.1002/hep.29519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。